Efficacy and safety of the Chaihuguizhiganjiang-suanzaoren granule on primary insomnia: study protocol for a randomised controlled trial
| Autor: | Jie Du, Tian He, Jie Zhang, Rong-Juan Guo, Ying-Zhen Xie, Cun-Zhi Liu, Jing Yang, Guang-Xia Shi, Qian-Qian Li, Xue-Qi Zhu, Jia-Lin Wang, Qing-Nan Fu, Qing-Quan Liu, Min-Min Wei |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Primary Insomnia Traditional Chinese medicine Placebo law.invention Pittsburgh Sleep Quality Index 03 medical and health sciences Young Adult 0302 clinical medicine Randomized controlled trial Double-Blind Method law ORAL MEDICINE Sleep Initiation and Maintenance Disorders Insomnia medicine Protocol Humans 030212 general & internal medicine Medicine Chinese Traditional Aged Sleep disorder business.industry General Medicine Middle Aged medicine.disease Clinical trial Treatment Outcome Neurology Research Design Physical therapy Female medicine.symptom business 030217 neurology & neurosurgery Drugs Chinese Herbal |
| Zdroj: | BMJ Open |
| ISSN: | 2044-6055 |
| Popis: | Introduction Insomnia is a highly prevalent, often debilitating and economically burdensome sleep disorder with limited effective therapies. Few data are available to understand which of the therapeutic alternatives is the most effective for patients with insomnia, especially for Traditional Chinese Medicine (TCM). Chinese herbal medicine, as a typical TCM, is one of the most popular complementary and alternative therapies for insomnia. We aim to evaluate the efficacy and safety of the Chaihuguizhiganjiang-suanzaoren granule (CSG), a Chinese herbal medicine treatment, in patients with primary insomnia. Methods and analysis This is a multicentre, placebo-controlled, double-blinded, randomised controlled clinical trial. A total of 258 participants are randomly allocated to two groups: the intervention group or the placebo group. The intervention group receives CSG and the placebo group receives a placebo granule. The patients receive either CSG or placebo two times daily for 8 weeks. The primary outcome is the Pittsburgh sleep quality index (PSQI). Secondary outcomes include the Insomnia Severity Index (ISI), Total Sleep Time (TST) and the Short-Form Health Survey (SF-36). The assessment is performed at baseline (before randomisation), 4, 8 and 12 weeks after randomisation. Ethics and dissemination The protocol has been approved by the Research Ethical Committee of Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University (reference: 2014BL-003-01). The trial will be helpful in identifying the efficacy and safety of CSG in patients with primary insomnia. Trial registration number ISRCTN22001145; Pre-results. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|